Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation. (1st July 2022)

• Record Type: Journal Article
• Authors: Abbasov, Emin; Metzner, Bernd; Müller, Thomas H.; Casper, Jochen; Kimmich, Christoph; Petershofen, Eduard K.; Renzelmann, Andrea; Rosien, Bernd; Thole, Ruth; Voß, Andreas; Köhne, Claus Henning
• Is Part Of: European journal of haematology. Volume 109:Number 3(2022)
• Page Start: 298
• Page End: 304
• Publication Date: 2022-07-01
• Subjects: acyclovir -- autologous stem‐cell transplantation -- herpes zoster -- malignant lymphoma -- multiple myeloma -- prophylaxis; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13810
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Background: Herpes zoster (HZ) is a frequent complication after autologous stem cell transplantation (ASCT). The option of zoster prophylaxis with an antiviral drug is described in the literature, but there is no consensus on the drug and the dosage. Patients and Methods: We analyzed the records of 310 patients treated with ASCT who were controlled regularly regarding HZ inter alia for at least 24 months following ASCT. Since 01/2015 patients received prophylactic low‐dose acyclovir (400 mg per day) during the first 12 months following discharge after ASCT ( n = 107). Results: Twenty percent of patients without this kind of prophylaxis and 2.8% of patients with prophylaxis developed HZ ( p < .001). No patient with this prophylaxis developed HZ in the first year after ASCT, 2.8% of patients in the second year after ASCT. A prognostic factor was the kind of diagnosis: 30% of lymphoma patients and 14% of myeloma patients developed HZ in the first 24 months after ASCT without prophylaxis, but only 6.3% and 0% of patients with prophylaxis, respectively. Neither an increase of HZ cases following prophylaxis nor acyclovir refractory HZ cases were observed. Conclusions: Zoster prophylaxis with low‐dose acyclovir over 12 months after ASCT is effective and well tolerated.